ACT News Alert Actavis Inc (ACT) 245.32 11/05/2014 04:53:59

New Post Public Reply Private Reply Replies (0) Message Board

Nov 5, 2014 at 5:53 AM

Actavis Inc (ACT) 245.32 $ACT

These 5 Drugmakers' Earnings Excelled This Quarter
at Investor's Business Daily - Tue Nov 04, 7:14PM CST
Big pharma firms such as Alexion Pharmaceuticals and Biogen Idec continue to outperform the market as they develop and market new treatments to treat long-time targets such as Alzheimer's as well as rare illnesses. Today's Screen Of The Day is Big...
AGN: 195.12 (+1.98), BIIB: 322.06 (+0.81), VRX: 133.61 (+0.76), ACT: 245.32 (-2.18), JAZZ: 168.48 (-1.85), ALXN: 191.30 (+0.26), CELG: 105.75 (-1.66)

Stocks End Mixed; Jazz Pharma Rises After Hours
at Investor's Business Daily - Tue Nov 04, 4:11PM CST
Stocks closed mixed, as earnings reports shook some stocks after the bell. The Nasdaq and S&P 500 dropped 0.3%, and the Dow Jones industrial average gained 0.1%. Volume was higher on the NYSE and lower on the Nasdaq, according to preliminary figures....
TSLA: 238.93 (-3.66), ACT: 245.32 (-2.18), FEYE: 34.25 (+0.56), AWAY: 33.75 (-1.11), CYBR: 36.53 (-0.05), JAZZ: 168.48 (-1.85), TRIP: 83.79 (-1.42), PANW: 106.71 (+0.75), ATHM: 50.19 (-0.40)

Will ARIAD (ARIA) Miss This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 4:00PM CST
ARIAD Pharmaceuticals, Inc. (ARIA) has Earnings ESP of 0.00% and a Zacks Rank #4 (Sell).
MNK: 94.09 (+0.66), ACT: 245.32 (-2.18), ARIA: 5.88 (-0.05), HSP: 53.28 (+0.26)

Will Endocyte (ECYT) Miss This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 3:50PM CST
Endocyte, Inc. (ECYT) has Earnings ESP of 0.00% and a Zacks Rank #2 (Buy).
ACT: 245.32 (-2.18), ECYT: 5.70 (-0.10), MRK: 59.37 (+0.45), HSP: 53.28 (+0.26)

Will Perrigo (PRGO) Disappoint This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 3:45PM CST
Perrigo (PRGO), which is scheduled to report first-quarter fiscal 2015 results on Nov 6, had delivered a positive earnings surprise of 12.26%.
MDVN: 103.83 (-1.57), ACT: 245.32 (-2.18), PRGO: 159.85 (-0.10), ALNY: 89.99 (-2.57)

Will Keryx Biopharmaceuticals (KERX) Post Wider Q3 Loss? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 3:35PM CST
Keryx Biopharmaceuticals, Inc.'s (KERX) is scheduled to report its third-quarter 2014 results on Nov 6.
MNK: 94.09 (+0.66), ACT: 245.32 (-2.18), HSP: 53.28 (+0.26), KERX: 16.30 (-0.15)

Video: Top 3 Earnings Reports To Watch Wednesday
at Investor's Business Daily - Tue Nov 04, 12:45PM CST
Several highly rated tech companies and drugmakers are set to report earnings on Wednesday. Here's a look at what analysts expect. Actavis (ACT) reports its results before the open. The specialty-drug giant is projected to earn $3.10 a share, a 48%...
AGN: 195.12 (+1.98), TSLA: 238.93 (-3.66), VRX: 133.61 (+0.76), ACT: 245.32 (-2.18), ATHM: 50.19 (-0.40)

Should You Buy Actavis (ACT) Ahead of Earnings? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 7:54AM CST
Actavis is seeing favorable earnings estimate revision activity and an earnings beat might be in the cards for the upcoming report.
ACT: 245.32 (-2.18)

Salix, Skyworks Lead 6 IBD50 EarningsReports On Tap
at Investor's Business Daily - Tue Nov 04, 7:02AM CST
Earnings season continues to barrel forward, and investors are anticipating results from several top drugmakers this upcoming week. This week's IBD 50, a roundup of top-rated growth stocks with solid fundamentals, boasts six companies reporting...
DRTX: 23.98 (-0.05), AGN: 195.12 (+1.98), ACT: 245.32 (-2.18), SWKS: 60.42 (+0.19), AKRX: 42.64 (-1.18), JAZZ: 168.48 (-1.85), SLXP: 140.45 (-2.74), AAPL: 108.60 (-0.80), ATHM: 50.19 (-0.40)

Can Cognizant (CTSH) Keep the Earnings Streak Alive? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 5:12PM CST
Cognizant Technology Solutions Corp (CTSH) is set to report third quarter 2014 results on Nov 5.
ACT: 245.32 (-2.18), DIS: 90.35 (-1.36), ACN: 81.15 (+0.18), CTSH: 48.49 (-0.40)

Will Actavis (ACT) Beat Earnings Estimates on Forest Deal? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 4:20PM CST
Actavis (ACT) is scheduled to report third-quarter 2014 results before the opening bell on Nov 5.
MNK: 94.09 (+0.66), ACT: 245.32 (-2.18), ALNY: 89.99 (-2.57), HSP: 53.28 (+0.26)

Is Hospira (HSP) Poised to Beat Q3 Earnings Estimates? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 4:00PM CST
Hospira (HSP), which is scheduled to report third-quarter 2014 results on Nov 6, had posted a positive earnings surprise of 28.57%.
MDVN: 103.83 (-1.57), ACT: 245.32 (-2.18), ALNY: 89.99 (-2.57), HSP: 53.28 (+0.26)

Will Covidien (COV) Disappoint Earnings Estimates in Q4? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 2:00PM CST
Covidien plc (COV) is set to report fourth-quarter fiscal 2014 results on Nov 5.
ACT: 245.32 (-2.18), MDT: 67.93 (-0.22), COV: 92.03 (-0.39), HSIC: 120.84 (+1.13)

Will Exelixis (EXEL) Disappoint This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 1:35PM CST
Exelixis, Inc. (EXEL) is slated to report its third-quarter 2014 results on Nov 4.
ACT: 245.32 (-2.18), HSP: 53.28 (+0.26), EXEL: 1.65 (-0.05)

Will Zoetis (ZTS) Pull a Surprise this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 4:10PM CDT
Zoetis Inc. (ZTS) is scheduled to report third-quarter 2014 results before the opening bell on Nov 4.
ZTS: 39.12 (+1.40), ACT: 245.32 (-2.18), PFE: 30.28 (+0.09), HSP: 53.28 (+0.26)

Bristol-Myers Squibb Up on Positive Opdivo Phase II Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 3:46PM CDT
Bristol-Myers Squibb Company announced encouraging data from the phase II CheckMate - 063 study on immuno-oncology drug Opdivo.
MNK: 94.09 (+0.66), AGN: 195.12 (+1.98), ACT: 245.32 (-2.18), BMY: 57.84 (+0.04)

Stocks End Week On Fine Note; LinkedIn Surges On Earnings
at Investor's Business Daily - Fri Oct 31, 3:29PM CDT
The market enjoyed another shot of institutional buying Friday, cheered by additional -- and unexpected -- stimulus measures by the Bank of Japan. Another round of healthy earnings reports and a rise in U.S. consumer confidence also fueled positive...
AMBA: 45.48 (-2.08), TSLA: 238.93 (-3.66), GPRO: 82.27 (-2.05), ACT: 245.32 (-2.18), FRGI: 55.42 (+0.20), LNKD: 238.43 (+5.35), JAZZ: 168.48 (-1.85), FLT: 148.53 (-1.70), EPAM: 46.61 (-1.10), REGN: 372.39 (-22.87), BABA: 106.07 (+4.27)

Actavis and Durata Therapeutics Receive U.S. FTC Clearance for Actavis' Proposed Acquisition of Durata
PR Newswire - Fri Oct 31, 3:15PM CDT
Actavis plc (NYSE: ACT) and Durata Therapeutics, Inc. (NASDAQ: DRTX) today announced that the U.S. Federal Trade Commission (FTC) has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR"

with respect to Actavis' pending acquisition of Durata.
DRTX: 23.98 (-0.05), ACT: 245.32 (-2.18)

Will Arena Pharma (ARNA) Q3 Loss Be Wider than Expected? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 2:34PM CDT
Arena Pharmaceuticals (ARNA) is scheduled to report its third-quarter 2014 results before the opening bell on Nov 3.
ACT: 245.32 (-2.18), ARNA: 4.31 (+0.09), HSP: 53.28 (+0.26)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Duolingo Lawsuit Looms Over Securities Allegations

Duolingo Lawsuit: A New Headache for Investors Seems like every time you blink, another tech darling is getting dragged to court, and now it's Duolingo's turn to face the music. They're locked in a class action lawsuit food-fight over violations of the Securities Exchange Act of 1934, specifically, §§10(b) and 20(a), and Rule 10b-5. The Core of Allegations Against...

IDrive Fortifies Data Protection with Top Certifications

Ramping up Security in a Complex World Data protection isn’t just yesterday’s crucial task—it's today's battlefield and tomorrow's war. Companies like IDrive are stepping up to the plate, offering solutions that are as sturdy as a brick wall. In a world where data breaches and hackers lurk like wolves in the shadows, the demand for secure, compliant data protection...

MSM's New Tool Tackles Label Errors with AI Insight

Nailing Label Precision in Real Time The label printing game just got a major new player. MSM Solutions is rolling out its PortalTrack Print Quality Inspection, and it's not just another tool in the shed—this thing's promising to cut down on label errors before they can bite. Imagine turning your good old industrial label printers into sharp-eyed inspectors, thanks to...

Innovative Sonar System Seeks to Simplify Fishing Boats

Navigating the Clutter on Fishing Boats You ever try setting up a sonar system on a fishing boat? It's like untangling a mess of Christmas lights. The cables, the hubs, the separate units—it’s chaos. Here's where a crafty inventor from Zumbro Falls, Minnesota, steps into the ring with an idea that's as refreshing as an ice-cold beer on a summer’s day: a centralized...

Quanta Services Reports Record Q3 2026 Earnings

Quanta Services Smashes Q3 2026 Expectations If you're a stakeholder in Quanta Services, you'd probably be dancing in the aisles right now. This company just posted off-the-charts numbers for the third quarter of 2026. We're talking revenues of $12 billion—a staggering leap from $7.63 billion the same quarter last year. Explosive Earnings and Strong Backlog The star of...

Viedoc and Bioforum Unite: Clinical Data Innovation

Revamping Clinical Trials with Data Integration It doesn't take a Wall Street wizard to understand that in today's research game, having data is only half the battle—using it effectively is where the rubber meets the road. Enter Viedoc and Bioforum, two names that are well-acquainted with the grind of the clinical research world. These seasoned pros have joined forces,...

OPC Energy Refinances $825M for U.S. Power Plants

Strategic Financial Move for OPC Energy Here's the scoop from the powerhouse behind some major U.S. electricity moves: OPC Energy and its subsidiary CPV nailed down a hefty $825 million financing package for the Shore and Maryland power plants. This isn’t just any old financial shuffle. Nope, they've hammered out an all-in-one refinancing deal that's setting the stage...

Duolingo Faces Legal Storm: Investors Called to Act

Stirring the Pot at Duolingo You know what's worse than learning a new language? Finding out the company teaching it might have pulled a few fast ones on the market. That's right, folks, buckle up because Duolingo (NASDAQ: DUOL) is in hot water with a class action lawsuit hanging over its head, like a cloud of bad grammar questions. What's Up with the Lawsuit? This isn't...

Veralto Sees Strong Q3 2026 Growth, Eyes 2027 Gains

Veralto's Stellar Third Quarter Performance Jumping right into the thick of it, Veralto's third quarter 2026 numbers aren't just a flash in the pan. We're talking a solid sales boost of 7.5%, reaching the magic number of $1,509 million. If you're holding NYSE:VLTO, these figures are a good look. It's not every day you see an operating profit margin hovered at an...

Rivercrest Unveils Inclusive Playground for All Kids

A New Playground Sparks Joy in Wilson, Arkansas The idea of building a playground sounds simple enough, right? But when Rivercrest School District decided to make it happen, they went all in. We’re not just talking swings and slides here. This $507,000 space at Rivercrest Elementary School is an inclusive haven where kids with different needs can just be kids, thanks to...